-transparent.png){kind=logo}
INF-alpha therapy has been a major development in the treatment of CML. Maturing experience has confirmed its ability to induce durable major cytogenetic remissions, which translate into durable long-term disease control, and change in the natural history of the disease. Future studies aimed at improving the percentage and quality of cytogenetic remissions by combining INF-alpha therapy with other chemotherapeutic agents and/or biologicals are needed. The goal would be to identify strategies that can consistently achieve a major cytogenetic response rate of 40% to 50% in the general community setting with acceptable morbidity. Continued studies of the interactions between INF -alpha therapy and transplant strategies will permit the optimization of treatment for each individual patient with CML.
S Giralt, and
H Kantarjian, and
M Talpaz
June 2004,
Hematology/oncology clinics of North America,
S Giralt, and
H Kantarjian, and
M Talpaz
January 1996,
Transplantation,
S Giralt, and
H Kantarjian, and
M Talpaz
June 2004,
Hematology/oncology clinics of North America,
S Giralt, and
H Kantarjian, and
M Talpaz
February 1993,
Gan to kagaku ryoho. Cancer & chemotherapy,
S Giralt, and
H Kantarjian, and
M Talpaz
July 1993,
Seminars in hematology,
S Giralt, and
H Kantarjian, and
M Talpaz
April 2000,
[Rinsho ketsueki] The Japanese journal of clinical hematology,
S Giralt, and
H Kantarjian, and
M Talpaz
October 1988,
Seminars in oncology,
S Giralt, and
H Kantarjian, and
M Talpaz
January 1989,
Cancer investigation,
S Giralt, and
H Kantarjian, and
M Talpaz
January 1998,
Archivum immunologiae et therapiae experimentalis,
S Giralt, and
H Kantarjian, and
M Talpaz
October 1995,
[Rinsho ketsueki] The Japanese journal of clinical hematology,
